

Cover Story
Neupogen, a drug widely used in oncology, recently received an FDA approval for boosting survival in people acutely exposed to myelosuppressive doses of radiation, also known as hematopoietic syndrome or acute radiation syndrome.
In Brief
Drugs & Targets
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out
- Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?